{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:43:35Z","timestamp":1777394615930,"version":"3.51.4"},"reference-count":34,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2017,6,5]]},"DOI":"10.3233\/jad-161252","type":"journal-article","created":{"date-parts":[[2017,5,16]],"date-time":"2017-05-16T12:56:13Z","timestamp":1494939373000},"page":"939-950","source":"Crossref","is-referenced-by-count":94,"title":["Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment"],"prefix":"10.1177","volume":"58","author":[{"given":"Steffen","family":"Wolfsgruber","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University of Bonn, Germany"},{"name":"German Center for Neurodegenerative Diseases, Bonn, Germany"}]},{"given":"Alexandra","family":"Polcher","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University of Bonn, Germany"},{"name":"German Center for Neurodegenerative Diseases, Bonn, Germany"}]},{"given":"Alexander","family":"Koppara","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University of Bonn, Germany"},{"name":"German Center for Neurodegenerative Diseases, Bonn, Germany"}]},{"given":"Luca","family":"Kleineidam","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University of Bonn, Germany"},{"name":"German Center for Neurodegenerative Diseases, Bonn, Germany"}]},{"given":"Lutz","family":"Fr\u00f6lich","sequence":"additional","affiliation":[{"name":"Department of Gerontopsychiatry, Central Institute of Mental Health, Mannheim, Germany"}]},{"given":"Oliver","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin, Germany"}]},{"given":"Michael","family":"H\u00fcll","sequence":"additional","affiliation":[{"name":"Center for Geriatric Medicine and Gerontology, University of Freiburg, Germany"}]},{"given":"Eckart","family":"R\u00fcther","sequence":"additional","affiliation":[{"name":"Department ofPsychiatry and Psychotherapy, University of G\u00f6ttingen, Germany"}]},{"given":"Jens","family":"Wiltfang","sequence":"additional","affiliation":[{"name":"Department ofPsychiatry and Psychotherapy, University of G\u00f6ttingen, Germany"}]},{"given":"Wolfgang","family":"Maier","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University of Bonn, Germany"},{"name":"German Center for Neurodegenerative Diseases, Bonn, Germany"}]},{"given":"Johannes","family":"Kornhuber","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Universit\u00e4tsklinikum Erlangen, and Friedrich-Alexander University Erlangen-N\u00fcrnberg, Erlangen, Germany"}]},{"given":"Piotr","family":"Lewczuk","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Universit\u00e4tsklinikum Erlangen, and Friedrich-Alexander University Erlangen-N\u00fcrnberg, Erlangen, Germany"},{"name":"Department of Neurodegeneration Diagnostics, Medical University of Bias\u0142ystok, and Departmentof Biochemical Diagnostics, University Hospital of Bialystok, Bialystok, Poland"}]},{"given":"Frank","family":"Jessen","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases, Bonn, Germany"},{"name":"Department of Psychiatry, University of Cologne, Germany"}]},{"given":"Michael","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University of Bonn, Germany"},{"name":"German Center for Neurodegenerative Diseases, Bonn, Germany"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-161252_ref1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-161252_ref2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","article-title":"A conceptual framework for research onsubjective cognitive decline in preclinical Alzheimer\u2019s disease","volume":"10","author":"Jessen","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-161252_ref3","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer\u2019s disease: Definition, natural history, and diagnostic criteria","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-161252_ref4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jalz.2012.08.004","article-title":"Cerebrospinal fluid A\u03b242 is the best predictor of clinical progression in patients with subjective complaints","volume":"9","author":"van Harten","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-161252_ref5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000439258","article-title":"Cerebrospinal fluid biomarkers predict clinical evolution inpatients with subjective cognitive decline and mild cognitiveimpairment","volume":"16","author":"Sierra-Rio","year":"2016","journal-title":"Neurodegener Dis"},{"key":"10.3233\/JAD-161252_ref6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1474-4422(09)70139-5","article-title":"Prevalence and prognostic value of CSF markers of Alzheimer\u2019s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study","volume":"8","author":"Visser","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-161252_ref7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000448326","article-title":"High prevalence of stress and low prevalence of Alzheimer disease CSF biomarkers in a clinical sample with subjective cognitive impairment","volume":"42","author":"Eckerstr\u00f6m","year":"2016","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-161252_ref8","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1212\/WNL.0b013e3182a8418b","article-title":"Preclinical AD predicts decline in memory and executive functions in subjective complaints","volume":"81","author":"van Harten","year":"2013","journal-title":"Neurology"},{"key":"10.3233\/JAD-161252_ref9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: Clinical characterization and outcome","volume":"56","author":"Petersen","year":"1999","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-161252_ref10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2796.2004.01380.x","article-title":"Mild cognitive impairment \u2013beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment","volume":"256","author":"Winblad","year":"2004","journal-title":"J Intern Med"},{"key":"10.3233\/JAD-161252_ref11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3233\/JAD-140276","article-title":"Neuropsychological criteria for mild cognitive impairment improvesdiagnostic precision, biomarker associations, and progressionrates","volume":"42","author":"Bondi","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-161252_ref12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00406-014-0571-z","article-title":"Considering the base rates of low performance in cognitively healthy older adults improves the accuracy to identify neurocognitive impairment with the Consortium to Establish a Registry for Alzheimer\u2019s Disease-Neuropsychological Assessment Battery (CERAD-NAB)","volume":"265","author":"Mistridis","year":"2015","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.3233\/JAD-161252_ref13","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jalz.2016.09.012","article-title":"Implementation of subjective cognitive decline criteria in research studies","volume":"13","author":"Molinuevo","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-161252_ref14","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1159\/000210388","article-title":"Early and differential diagnosis of dementia and mild cognitive impairment","volume":"27","author":"Kornhuber","year":"2009","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-161252_ref15","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00702-006-0511-9","article-title":"The German Competence Net Dementias: Standard operating procedures for the neurochemical dementia diagnostics","volume":"113","author":"Lewczuk","year":"2006","journal-title":"J Neural Transm"},{"key":"10.3233\/JAD-161252_ref16","first-page":"273","article-title":"Neurochemical diagnosis of Alzheimer\u2019s dementia by CSFAbeta42, Abeta42\/Abeta40 ratio and total tau","volume":"25","author":"Lewczuk","year":"2004","journal-title":"NeurobiolAging"},{"key":"10.3233\/JAD-161252_ref17","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jalz.2013.12.023","article-title":"Thecerebrospinal fluid \u201cAlzheimer profile\u201d: Easily said, but whatdoes it mean?","volume":"10","author":"Duits","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-161252_ref18","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.52.8.1555","article-title":"Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF","volume":"52","author":"Hulstaert","year":"1999","journal-title":"Neurology"},{"key":"10.3233\/JAD-161252_ref19","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1212\/WNL.39.9.1159","article-title":"The Consortium to Establish a Registry for Alzheimer\u2019s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer\u2019s disease","volume":"39","author":"Morris","year":"1989","journal-title":"Neurology"},{"key":"10.3233\/JAD-161252_ref20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.3233\/JAD-161252_ref21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2466\/pms.1958.8.3.271","article-title":"Validity of the Trail Making Test as an indicator of organic brain damage","volume":"8","author":"Reitan","year":"1958","journal-title":"Percept Mot Skills"},{"key":"10.3233\/JAD-161252_ref23","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"10.3233\/JAD-161252_ref24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0165-0327(02)00120-9","article-title":"Differentiating moderate and severe depression using theMontgomery\u2013\u212bsberg depression rating scale(MADRS)","volume":"77","author":"M\u00fcller","year":"2003","journal-title":"J Affect Disord"},{"issue":"Suppl 2","key":"10.3233\/JAD-161252_ref25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000051195","article-title":"The bayer activities of daily living scale (B-ADL)","volume":"9","author":"Hindmarch","year":"1998","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-161252_ref26","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/archneurol.2011.3029","article-title":"Comparison of imaging biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging","volume":"69","author":"Whitwell","year":"2012","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-161252_ref27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jalz.2012.09.017","article-title":"AD dementia risk in late MCI, in early MCI, and in subjective memory impairment","volume":"10","author":"Jessen","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-161252_ref28","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons withoutdementia: A meta-analysis","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"key":"10.3233\/JAD-161252_ref29","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1001\/jama.2015.9716","article-title":"Amyloid pathology, cognitive impairment, and Alzheimer disease risk","volume":"314","author":"Wagner","year":"2015","journal-title":"JAMA"},{"key":"10.3233\/JAD-161252_ref30","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jalz.2016.08.011","article-title":"Subjective cognitive decline in cognitivelynormal elders from the community or from a memory clinic:Differential affective and imaging correlates","volume":"13","author":"Perrotin","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-161252_ref31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","article-title":"Mild cognitive impairment as a diagnostic entity","volume":"256","author":"Petersen","year":"2004","journal-title":"J Intern Med"},{"key":"10.3233\/JAD-161252_ref32","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3233\/JAD-150342","article-title":"Validation of the Erlangen score algorithm for the prediction of the development of dementia due to Alzheimer\u2019s disease in pre-dementia subjects","volume":"48","author":"Lewczuk","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-161252_ref33","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1212\/WNL.0b013e3182563bbe","article-title":"Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease","volume":"78","author":"Knopman","year":"2012","journal-title":"Neurology"},{"key":"10.3233\/JAD-161252_ref34","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1474-4422(13)70194-7","article-title":"PreclinicalAlzheimer\u2019s disease and its outcome:A longitudinal cohortstudy","volume":"12","author":"Vos","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-161252_ref35","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-161252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:03:49Z","timestamp":1777370629000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-161252"}},"subtitle":[],"editor":[{"given":"Andrea","family":"Tales","sequence":"additional","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2017,6,5]]},"references-count":34,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jad-161252","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,5]]}}}